Connect Biopharma is trading $1.94 (+5.34%) after-hours amid possible investor positioning ahead of expected September results from two Phase 2 Seabreeze studies.
- It closed September 4, 2026, at $1.84 after falling 4.66% during regular trading.
- No verified company-specific announcement or earnings release explains the rebound; the move remains speculative, with limited confirmation of a direct catalyst.
- Management’s next scheduled event is a September 15 H.C. Wainwright presentation.